The glioblastoma market is witnessing significant advancements propelled by novel therapies and increasing demand for effective treatment options.

Market Size and Overview The glioblastoma market is estimated to be valued at USD 1.30 Bn in 2025 and is expected to reach USD 3.12 Bn by 2032, growing at a compound annual growth rate (CAGR) of 13.3% from 2025 to 2032.

This upward trajectory is driven by breakthroughs in immunotherapy and personalized medicine approaches, as well as the increasing incidence of glioblastoma worldwide. The Glioblastoma Market report highlights robust growth supported by enhanced diagnostic tools and expanded access to specialized care facilities.

Market Segments The glioblastoma market can be segmented primarily into treatment modalities, region, and end user.

• Treatment Modalities: Includes surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Among these, immunotherapy remains the dominant segment, registering faster growth due to advances in CAR-T cell therapy and oncolytic virus treatments demonstrated in 2024 clinical trials.
• End Users: Hospitals, ambulatory surgical centers, and cancer research institutes. Hospitals dominate revenue generation, while ambulatory surgical centers are the fastest-growing due to increasing outpatient therapeutic interventions.
• Region: North America, Europe, Asia Pacific, and others. The Asia Pacific market is witnessing accelerated growth, supported by increasing healthcare infrastructure investments and growing patient awareness.

‣ Glioblastoma Market: https://www.coherentmi.com/industry-reports/glioblastoma-market